Lam Research's Record Quarter Meets a Supply-Constrained Outlook

Lam Research's record quarter did not prevent a sharp selloff because investors focused on what comes next. Revenue for the quarter ended September 27 reached $8.22 billion, up 54% from a year earlier, while non-GAAP operating margin hit 40.2% and non-GAAP diluted earnings were $2.20 a share. Yet the stock fell after management guided to December-quarter revenue of $8.6 billion, plus or minus $400 million, and non-GAAP earnings of $2.33, plus or minus $0.10.

The tension is between demand and delivery. Management said shortages of certain components limited the December outlook and that some delayed shipments should move into the March quarter. If that explanation holds, the near-term revenue gap is timing rather than lost business. It does not remove execution risk, however. A component shortage can still delay customer installations, raise costs and make quarterly estimates less reliable.

China adds a separate complication. The original report said the country represented 35% of September-quarter revenue and is expected to decline sharply in the December quarter. That mix shift matters because export restrictions and customer spending patterns can change independently of the broader memory cycle. Investors should not treat a shipment delay and lower China exposure as the same issue.

The valuation argument is more attractive after the decline, but it depends on forecasts that can move. The source reported Lam at about 22 times forward earnings, below its five-year average of 24 times, and cited Bernstein's $350 target. Those comparisons are not a substitute for cash flows. They assume wafer-fabrication equipment spending remains strong and that analysts' projected earnings growth survives any slowdown in AI infrastructure spending.

The operating evidence is still constructive. Lam's official release confirmed the record revenue, margin and earnings figures, while the source said management expects preliminary 2027 wafer-fabrication equipment spending above $200 billion, led by DRAM. The important test is whether the December quarter lands within guidance and whether delayed shipments appear in the March quarter without a corresponding rise in cancellations.

Lam therefore presents a specific, falsifiable setup. If supply availability improves while customer demand remains intact, the recent decline may have overstated the damage. If capital spending weakens or China falls faster than expected, the earnings estimates behind the valuation case will need to come down.